{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:01:23Z","timestamp":1792008083317,"version":"4.4.0"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1038\/s41582-021-00465-0","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T14:10:28Z","timestamp":1614780628000},"page":"381-392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["hiPSCs for predictive modelling of neurodegenerative diseases: dreaming the possible"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5999-1230","authenticated-orcid":false,"given":"Pia","family":"Rivetti di Val Cervo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Besusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Conforti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0755-4917","authenticated-orcid":false,"given":"Elena","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,3]]},"reference":[{"key":"465_CR1","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861\u2013872 (2007).","journal-title":"Cell"},{"key":"465_CR2","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1126\/science.1151526","volume":"318","author":"J Yu","year":"2007","unstructured":"Yu, J. et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 318, 1917\u20131920 (2007).","journal-title":"Science"},{"key":"465_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrd.2016.245","volume":"16","author":"Y Shi","year":"2017","unstructured":"Shi, Y., Inoue, H., Wu, J. C. & Yamanaka, S. Induced pluripotent stem cell technology: a decade of progress. Nat. Rev. Drug Discov. 16, 115\u2013130 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"465_CR4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2008.02.010","volume":"132","author":"LL Rubin","year":"2008","unstructured":"Rubin, L. L. Stem cells and drug discovery: the beginning of a new era? Cell 132, 549\u2013552 (2008).","journal-title":"Cell"},{"key":"465_CR5","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.3390\/v7072800","volume":"7","author":"M Trevisan","year":"2015","unstructured":"Trevisan, M. et al. Modeling viral infectious diseases and development of antiviral therapies using human induced pluripotent stem cell-derived systems. Viruses 7, 3835\u20133856 (2015).","journal-title":"Viruses"},{"key":"465_CR6","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.stem.2020.09.013","volume":"27","author":"J Huang","year":"2020","unstructured":"Huang, J. et al. SARS-CoV-2 infection of pluripotent stem cell-derived human lung alveolar type 2 cells elicits a rapid epithelial-intrinsic inflammatory response. Cell Stem Cell 27, 962\u2013973.e7 (2020).","journal-title":"Cell Stem Cell"},{"key":"465_CR7","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.stem.2017.01.011","volume":"20","author":"MA Cayo","year":"2017","unstructured":"Cayo, M. A. et al. A drug screen using human iPSC-derived hepatocyte-like cells reveals cardiac glycosides as a potential treatment for hypercholesterolemia. Cell Stem Cell 20, 478\u2013489.e5 (2017).","journal-title":"Cell Stem Cell"},{"key":"465_CR8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2472630318803277","volume":"24","author":"RM Eglen","year":"2019","unstructured":"Eglen, R. M. & Reisine, T. Human iPS cell-derived patient tissues and 3D cell culture part 1: target identification and lead optimization. SLAS Technol. 24, 3\u201317 (2019).","journal-title":"SLAS Technol."},{"key":"465_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/srep12337","volume":"5","author":"K Kandasamy","year":"2015","unstructured":"Kandasamy, K. et al. Prediction of drug-induced nephrotoxicity and injury mechanisms with human induced pluripotent stem cell-derived cells and machine learning methods. Sci. Rep. 5, 12337 (2015).","journal-title":"Sci. Rep."},{"key":"465_CR10","doi-asserted-by":"publisher","first-page":"180177","DOI":"10.1098\/rsob.180177","volume":"9","author":"Y-Y Wu","year":"2019","unstructured":"Wu, Y.-Y., Chiu, F.-L., Yeh, C.-S. & Kuo, H.-C. Opportunities and challenges for the use of induced pluripotent stem cells in modelling neurodegenerative disease. Open Biol. 9, 180177 (2019).","journal-title":"Open Biol."},{"key":"465_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00441-017-2713-x","volume":"371","author":"L Li","year":"2018","unstructured":"Li, L., Chao, J. & Shi, Y. Modeling neurological diseases using iPSC-derived neural cells: iPSC modeling of neurological diseases. Cell Tissue Res. 371, 143\u2013151 (2018).","journal-title":"Cell Tissue Res."},{"key":"465_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.stem.2015.06.013","volume":"17","author":"J McNeish","year":"2015","unstructured":"McNeish, J., Gardner, J. P., Wainger, B. J., Woolf, C. J. & Eggan, K. From dish to bedside: lessons learned while translating findings from a stem cell model of disease to a clinical trial. Cell Stem Cell 17, 8\u201310 (2015).","journal-title":"Cell Stem Cell"},{"key":"465_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.tips.2019.12.002","volume":"41","author":"H Okano","year":"2020","unstructured":"Okano, H., Yasuda, D., Fujimori, K., Morimoto, S. & Takahashi, S. Ropinirole, a new ALS drug candidate developed using iPSCs. Trends Pharmacol. Sci. 41, 99\u2013109 (2020).","journal-title":"Trends Pharmacol. Sci."},{"key":"465_CR14","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/cpt.1096","volume":"104","author":"MO Kovalchuk","year":"2018","unstructured":"Kovalchuk, M. O. et al. Acute effects of riluzole and retigabine on axonal excitability in patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled, crossover trial. Clin. Pharmacol. Ther. 104, 1136\u20131145 (2018).","journal-title":"Clin. Pharmacol. Ther."},{"key":"465_CR15","doi-asserted-by":"publisher","first-page":"9166","DOI":"10.1002\/jcp.29800","volume":"235","author":"N Yousefi","year":"2020","unstructured":"Yousefi, N., Abdollahii, S., Kouhbanani, M. A. J. & Hassanzadeh, A. Induced pluripotent stem cells (iPSCs) as game-changing tools in the treatment of neurodegenerative disease: mirage or reality? J. Cell. Physiol. 235, 9166\u20139184 (2020).","journal-title":"J. Cell. Physiol."},{"key":"465_CR16","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s10529-020-02886-1","volume":"42","author":"H Ahmadian-Moghadam","year":"2020","unstructured":"Ahmadian-Moghadam, H., Sadat-Shirazi, M. S. & Zarrindast, M. R. Therapeutic potential of stem cells for treatment of neurodegenerative diseases. Biotechnol. Lett. 42, 1073\u20131101 (2020).","journal-title":"Biotechnol. Lett."},{"key":"465_CR17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.brainres.2015.06.053","volume":"1638","author":"M Levy","year":"2016","unstructured":"Levy, M., Boulis, N., Rao, M. & Svendsen, C. N. Regenerative cellular therapies for neurologic diseases. Brain Res. 1638, 88\u201396 (2016).","journal-title":"Brain Res."},{"key":"465_CR18","doi-asserted-by":"publisher","first-page":"101581","DOI":"10.1016\/j.scr.2019.101581","volume":"41","author":"TE Allsopp","year":"2019","unstructured":"Allsopp, T. E., Ebneth, A. & Cabrera-Socorro, A. Deploying human pluripotent stem cells to treat central nervous system disorders: facts, challenges and realising the potential. Stem Cell Res. 41, 101581 (2019).","journal-title":"Stem Cell Res."},{"key":"465_CR19","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1915872","volume":"382","author":"JS Schweitzer","year":"2020","unstructured":"Schweitzer, J. S. et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson\u2019s disease. N. Engl. J. Med. 382, 1926\u20131932 (2020).","journal-title":"N. Engl. J. Med."},{"key":"465_CR20","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.stemcr.2018.06.012","volume":"11","author":"A Guhr","year":"2018","unstructured":"Guhr, A. et al. Recent trends in research with human pluripotent stem cells: impact of research and use of cell lines in experimental research and clinical trials. Stem Cell Rep. 11, 485\u2013496 (2018).","journal-title":"Stem Cell Rep."},{"key":"465_CR21","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/sctm.18-0088","volume":"8","author":"RM Marton","year":"2019","unstructured":"Marton, R. M. & Ioannidis, J. P. A. A comprehensive analysis of protocols for deriving dopaminergic neurons from human pluripotent stem cells. Stem Cell Transl. Med. 8, 366\u2013374 (2019).","journal-title":"Stem Cell Transl. Med."},{"key":"465_CR22","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nbt.1529","volume":"27","author":"SM Chambers","year":"2009","unstructured":"Chambers, S. M. et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 27, 275\u2013280 (2009).","journal-title":"Nat. Biotechnol."},{"key":"465_CR23","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature10648","volume":"480","author":"S Kriks","year":"2011","unstructured":"Kriks, S. et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson\u2019s disease. Nature 480, 547\u2013551 (2011).","journal-title":"Nature"},{"key":"465_CR24","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1073\/pnas.0910012107","volume":"107","author":"B-Y Hu","year":"2010","unstructured":"Hu, B.-Y. et al. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc. Natl Acad. Sci. USA 107, 4335\u20134340 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"465_CR25","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/ncb3313","volume":"18","author":"MP Yaffe","year":"2016","unstructured":"Yaffe, M. P., Noggle, S. A. & Solomon, S. L. Raising the standards of stem cell line quality. Nat. Cell Biol. 18, 236\u2013237 (2016).","journal-title":"Nat. Cell Biol."},{"key":"465_CR26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature09342","volume":"467","author":"K Kim","year":"2010","unstructured":"Kim, K. et al. Epigenetic memory in induced pluripotent stem cells. Nature 467, 285\u2013290 (2010).","journal-title":"Nature"},{"key":"465_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.32607\/20758251-2013-5-4-15-21","volume":"5","author":"EA Vaskova","year":"2013","unstructured":"Vaskova, E. A., Stekleneva, A. E., Medvedev, S. P. & Zakian, S. M. \u2018Epigenetic memory\u2019 phenomenon in induced pluripotent stem cells. Acta Naturae 5, 15\u201321 (2013).","journal-title":"Acta Naturae"},{"key":"465_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nbt.3749","volume":"35","author":"V Lo Sardo","year":"2017","unstructured":"Lo Sardo, V. et al. Influence of donor age on induced pluripotent stem cells. Nat. Biotechnol. 35, 69\u201374 (2017).","journal-title":"Nat. Biotechnol."},{"key":"465_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2013-14-10-r115","volume":"14","author":"S Horvath","year":"2013","unstructured":"Horvath, S. DNA methylation age of human tissues and cell types. Genome Biol. 14, R115 (2013).","journal-title":"Genome Biol."},{"key":"465_CR30","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.18648","volume":"5","author":"CJ Huh","year":"2016","unstructured":"Huh, C. J. et al. Maintenance of age in human neurons generated by microRNA-based neuronal conversion of fibroblasts. eLife 5, e18648 (2016).","journal-title":"eLife"},{"key":"465_CR31","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.stem.2016.02.005","volume":"18","author":"E Kang","year":"2016","unstructured":"Kang, E. et al. Age-related accumulation of somatic mitochondrial DNA mutations in adult-derived human iPSCs. Cell Stem Cell 18, 625\u2013636 (2016).","journal-title":"Cell Stem Cell"},{"key":"465_CR32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.stem.2016.09.004","volume":"20","author":"A Kirkeby","year":"2017","unstructured":"Kirkeby, A. et al. Predictive markers guide differentiation to improve graft outcome in clinical translation of hESC-based therapy for Parkinson\u2019s disease. Cell Stem Cell 20, 135\u2013148 (2017).","journal-title":"Cell Stem Cell"},{"key":"465_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.stem.2016.10.003","volume":"20","author":"N Kee","year":"2017","unstructured":"Kee, N. et al. Single-cell analysis reveals a close relationship between differentiating dopamine and subthalamic nucleus neuronal lineages. Cell Stem Cell 20, 29\u201340 (2017).","journal-title":"Cell Stem Cell"},{"key":"465_CR34","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.stemcr.2016.05.001","volume":"6","author":"GQ Daley","year":"2016","unstructured":"Daley, G. Q. et al. Setting global standards for stem cell research and clinical translation: the 2016 ISSCR guidelines. Stem Cell Rep. 6, 787\u2013797 (2016).","journal-title":"Stem Cell Rep."},{"key":"465_CR35","unstructured":"International Society for Stem Cell Research. Guidelines for Stem Cell Research and Clinical Translation (ISSCR, 2016)."},{"key":"465_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.scr.2017.03.002","volume":"20","author":"PA De Sousa","year":"2017","unstructured":"De Sousa, P. A. et al. Rapid establishment of the European Bank for induced Pluripotent Stem Cells (EBiSC) \u2013 the Hot Start experience. Stem Cell Res. 20, 105\u2013114 (2017).","journal-title":"Stem Cell Res."},{"key":"465_CR37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12929-019-0578-x","volume":"26","author":"CY Huang","year":"2019","unstructured":"Huang, C. Y. et al. Human iPSC banking: barriers and opportunities. J. Biomed. Sci. 26, 87 (2019).","journal-title":"J. Biomed. Sci."},{"key":"465_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/0268-960X(95)90036-5","volume":"9","author":"E Harvey","year":"1995","unstructured":"Harvey, E., Hewison, C., Nevalainen, D. E. & Lloyd, H. L. Maintaining quality in blood banking. Blood Rev. 9, 15\u201324 (1995).","journal-title":"Blood Rev."},{"key":"465_CR39","doi-asserted-by":"publisher","first-page":"101851","DOI":"10.1016\/j.scr.2020.101851","volume":"46","author":"J Toombs","year":"2020","unstructured":"Toombs, J. et al. Generation of twenty four induced pluripotent stem cell lines from twenty four members of the Lothian Birth Cohort 1936. Stem Cell Res. 46, 101851 (2020).","journal-title":"Stem Cell Res."},{"key":"465_CR40","doi-asserted-by":"crossref","unstructured":"Sarvari, M., Alavi-Moghadam, S., Larijani, B., Rezazadeh, I. & Arjmand, B. in Biomedical Product Development: Bench to Bedside, Ch 6 (eds Arjmand, B., Payab, M. & Goodarzi, P.) 61\u201368 (Springer, 2020).","DOI":"10.1007\/978-3-030-35626-2_6"},{"key":"465_CR41","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.stem.2017.09.014","volume":"21","author":"RA Barker","year":"2017","unstructured":"Barker, R. A., Parmar, M., Studer, L. & Takahashi, J. Human trials of stem cell-derived dopamine neurons for Parkinson\u2019s disease: dawn of a new era. Cell Stem Cell 21, 569\u2013573 (2017).","journal-title":"Cell Stem Cell"},{"key":"465_CR42","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41380-019-0495-0","volume":"25","author":"KM Lee","year":"2020","unstructured":"Lee, K. M. et al. The application of human pluripotent stem cells to model the neuronal and glial components of neurodevelopmental disorders. Mol. Psychiatry 25, 368\u2013378 (2020).","journal-title":"Mol. Psychiatry"},{"key":"465_CR43","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrneurol.2017.45","volume":"13","author":"K Ardhanareeswaran","year":"2017","unstructured":"Ardhanareeswaran, K., Mariani, J., Coppola, G., Abyzov, A. & Vaccarino, F. M. Normal development of neuronal networks requires a delicate balance of proliferation and differentiation of specific neuronal lineages, and appropriate migration and integration of these specific neuronal subtypes into neuronal circuits. Nat.Rev. Neurol. 13, 265\u2013278 (2017).","journal-title":"Nat.Rev. Neurol."},{"key":"465_CR44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s13238-019-0638-8","volume":"11","author":"M Wang","year":"2020","unstructured":"Wang, M., Zhang, L. & Gage, F. H. Modeling neuropsychiatric disorders using human induced pluripotent stem cells. Protein Cell 11, 45\u201359 (2020).","journal-title":"Protein Cell"},{"key":"465_CR45","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1016\/j.bbadis.2017.06.019","volume":"1863","author":"H Noh","year":"2017","unstructured":"Noh, H., Shao, Z., Coyle, J. T. & Chung, S. Modeling schizophrenia pathogenesis using patient-derived induced pluripotent stem cells (iPSCs). Biochim. Biophys. Acta Mol. Basis Dis. 1863, 2382\u20132387 (2017).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"465_CR46","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.3390\/ijms21062239","volume":"21","author":"M Csobonyeiova","year":"2020","unstructured":"Csobonyeiova, M., Polak, S. & Danisovic, L. Recent overview of the use of iPSCs Huntington\u2019s disease modeling and therapy. Int. J. Mol. Sci. 21, 2239 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"465_CR47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/2096595819896178","volume":"5","author":"F Han","year":"2019","unstructured":"Han, F. et al. The application of patient-derived induced pluripotent stem cells for modeling and treatment of Alzheimer\u2019s disease. Brain Sci. Adv. 5, 21\u201340 (2019).","journal-title":"Brain Sci. Adv."},{"key":"465_CR48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12929-019-0501-5","volume":"26","author":"F Majolo","year":"2019","unstructured":"Majolo, F., Marinowic, D. R., MacHado, D. C. & Da Costa, J. C. Important advances in Alzheimer\u2019s disease from the use of induced pluripotent stem cells. J. Biomed. Sci. 26, 15 (2019).","journal-title":"J. Biomed. Sci."},{"key":"465_CR49","doi-asserted-by":"publisher","first-page":"634","DOI":"10.4252\/wjsc.v11.i9.634","volume":"11","author":"M Ke","year":"2019","unstructured":"Ke, M., Chong, C. M. & Su, H. Using induced pluripotent stem cells for modeling Parkinson\u2019s disease. World J. Stem Cell 11, 634\u2013649 (2019).","journal-title":"World J. Stem Cell"},{"key":"465_CR50","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nrneurol.2016.196","volume":"13","author":"AJ Espay","year":"2017","unstructured":"Espay, A. J., Brundin, P. & Lang, A. E. Precision medicine for disease modification in Parkinson disease. Nat. Rev. Neurol. 13, 119\u2013126 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"465_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-40","volume":"5","author":"RAC Roos","year":"2010","unstructured":"Roos, R. A. C. et al. Huntington\u2019s disease: a clinical review. Orphanet J. Rare Dis. 5, 40 (2010).","journal-title":"Orphanet J. Rare Dis."},{"key":"465_CR52","doi-asserted-by":"crossref","unstructured":"Geater, C., Hernandez, S., Thompson, L. & Mattis, V. B. in Huntington\u2019s Disease. (eds Precious, S., Rosser, A. & Dunnett, S.) 41\u201373 (Humana, 2018). [Series Methods in Molecular Biology Vol. 1780].","DOI":"10.1007\/978-1-4939-7825-0_4"},{"key":"465_CR53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1167\/iovs.61.8.11","volume":"61","author":"J Ledolter","year":"2020","unstructured":"Ledolter, J. & Kardon, R. H. Focus on data: statistical design of experiments and sample size selection using power analysis. Investig. Ophthalmol. Vis. Sci. 61, 11 (2020).","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"465_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47123-6","volume":"9","author":"F Regent","year":"2019","unstructured":"Regent, F. et al. Automation of human pluripotent stem cell differentiation toward retinal pigment epithelial cells for large-scale productions. Sci. Rep. 9, 10646 (2019).","journal-title":"Sci. Rep."},{"key":"465_CR55","doi-asserted-by":"publisher","unstructured":"Dhingra, A. et al. Automated production of human induced pluripotent stem cell-derived cortical and dopaminergic neurons with integrated live-cell monitoring. J. Vis. Exp. 2020, https:\/\/doi.org\/10.3791\/61525 (2020).","DOI":"10.3791\/61525"},{"key":"465_CR56","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.celrep.2017.12.013","volume":"22","author":"A Virlogeux","year":"2018","unstructured":"Virlogeux, A. et al. Reconstituting corticostriatal network on-a-chip reveals the contribution of the presynaptic compartment to Huntington\u2019s disease. Cell Rep. 22, 110\u2013122 (2018).","journal-title":"Cell Rep."},{"key":"465_CR57","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.biomaterials.2017.10.002","volume":"154","author":"P Zhuang","year":"2018","unstructured":"Zhuang, P., Sun, A. X., An, J., Chua, C. K. & Chew, S. Y. 3D neural tissue models: from spheroids to bioprinting. Biomaterials 154, 113\u2013133 (2018).","journal-title":"Biomaterials"},{"key":"465_CR58","doi-asserted-by":"publisher","first-page":"146393","DOI":"10.1016\/j.brainres.2019.146393","volume":"1723","author":"F Salaris","year":"2019","unstructured":"Salaris, F. & Rosa, A. Construction of 3D in vitro models by bioprinting human pluripotent stem cells: challenges and opportunities. Brain Res. 1723, 146393 (2019).","journal-title":"Brain Res."},{"key":"465_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0079-3","author":"LA Low","year":"2020","unstructured":"Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P. & Tagle, D. A. Organs-on-chips: into the next decade. Nat. Rev. Drug Discov. https:\/\/doi.org\/10.1038\/s41573-020-0079-3 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"465_CR60","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41580-020-0259-3","volume":"21","author":"J Kim","year":"2020","unstructured":"Kim, J., Koo, B. K. & Knoblich, J. A. Human organoids: model systems for human biology and medicine. Nat. Rev. Mol. Cell Biol. 21, 571\u2013584 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"465_CR61","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/s41587-020-00763-w","volume":"38","author":"Y Miura","year":"2020","unstructured":"Miura, Y. et al. Generation of human striatal organoids and cortico-striatal assembloids from human pluripotent stem cells. Nat. Biotechnol. 38, 1421\u20131430 (2020).","journal-title":"Nat. Biotechnol."},{"key":"465_CR62","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.addr.2018.01.017","volume":"136\u2013137","author":"A Fortunato","year":"2018","unstructured":"Fortunato, A., Grainger, D. W. & Abou-El-Enein, M. Enhancing patient-level clinical data access to promote evidence-based practice and incentivize therapeutic innovation. Adv. Drug Deliv. Rev. 136\u2013137, 97\u2013104 (2018).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"465_CR63","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/13697137.2017.1287866","volume":"20","author":"H Hampel","year":"2017","unstructured":"Hampel, H. et al. A precision medicine initiative for Alzheimer\u2019s disease: the road ahead to biomarker-guided integrative disease modeling. Climacteric 20, 107\u2013118 (2017).","journal-title":"Climacteric"},{"key":"465_CR64","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1878-5085-4-23","volume":"4","author":"E Younesi","year":"2013","unstructured":"Younesi, E. & Hofmann-Apitius, M. From integrative disease modeling to predictive, preventive, personalized and participatory (P4) medicine. EPMA J. 4, 23 (2013).","journal-title":"EPMA J."},{"key":"465_CR65","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.2147\/IJGM.S285262","volume":"13","author":"N Ielapi","year":"2020","unstructured":"Ielapi, N. et al. Precision medicine and precision nursing: the era of biomarkers and precision health. Int. J. Gen. Med. 13, 1705 (2020).","journal-title":"Int. J. Gen. Med."},{"key":"465_CR66","first-page":"243","volume":"3","author":"HJ Hampel","year":"2016","unstructured":"Hampel, H. J., Bryant, S. E. O., Castrillo, J. I. & Ritchie, C. PRECISION MEDICINE - the golden gate for detection, treatment and prevention of Alzheimer\u2019s disease. J. Prev. Alzheimers Dis. 3, 243\u2013259 (2016).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"465_CR67","first-page":"70","volume":"6","author":"P Krzyszczyk","year":"2019","unstructured":"Krzyszczyk, P. et al. The growing role of precision and personalized medicine for cancer treatment. Technology 6, 70\u2013100 (2019).","journal-title":"Technology"},{"key":"465_CR68","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.3390\/cancers11121988","volume":"11","author":"M Boufraqech","year":"2019","unstructured":"Boufraqech, M. & Nilubol, N. Multi-omics signatures and translational potential to improve thyroid cancer patient outcome. Cancers 11, 1988 (2019).","journal-title":"Cancers"},{"key":"465_CR69","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-019-0447-x","volume":"25","author":"D Ardila","year":"2019","unstructured":"Ardila, D. et al. End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. Nat. Med. 25, 954\u2013961 (2019).","journal-title":"Nat. Med."},{"key":"465_CR70","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12901","volume":"48","author":"M Rabbani","year":"2018","unstructured":"Rabbani, M. et al. Role of artificial intelligence in the care of patients with nonsmall cell lung cancer. Eur. J. Clin. Invest. 48, e12901 (2018).","journal-title":"Eur. J. Clin. Invest."},{"key":"465_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06921-8","volume":"9","author":"D Ramazzotti","year":"2018","unstructured":"Ramazzotti, D., Lal, A., Wang, B., Batzoglou, S. & Sidow, A. Multi-omic tumor data reveal diversity of molecular mechanisms that correlate with survival. Nat. Commun. 9, 4453 (2018).","journal-title":"Nat. Commun."},{"key":"465_CR72","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3389\/fneur.2019.00400","volume":"10","author":"V Bonetto","year":"2019","unstructured":"Bonetto, V. et al. A systematic review of suggested molecular strata, biomarkers and their tissue sources in ALS. Front. Neurol. 10, 400 (2019).","journal-title":"Front. Neurol."},{"key":"465_CR73","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.3233\/JAD-179932","volume":"64","author":"H Hampel","year":"2018","unstructured":"Hampel, H. et al. Revolution of Alzheimer precision neurology. Passageway of systems biology and neurophysiology. J. Alzheimer\u2019s Dis. 64, S47\u2013S105 (2018).","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"465_CR74","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/cts.12674","volume":"12","author":"K Blinova","year":"2019","unstructured":"Blinova, K. et al. Clinical trial in a dish: personalized stem cell-derived cardiomyocyte assay compared with clinical trial results for two QT-prolonging drugs. Clin. Transl. Sci. 12, 687\u2013697 (2019).","journal-title":"Clin. Transl. Sci."},{"key":"465_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-016-0169-4","volume":"16","author":"K Tucker","year":"2016","unstructured":"Tucker, K. et al. Protecting patient privacy when sharing patient-level data from clinical trials. BMC Med. Res. Methodol. 16, 77 (2016).","journal-title":"BMC Med. Res. Methodol."},{"key":"465_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1122-7","volume":"16","author":"H Fr\u00f6hlich","year":"2018","unstructured":"Fr\u00f6hlich, H. et al. From hype to reality: data science enabling personalized medicine. BMC Med. 16, 150 (2018).","journal-title":"BMC Med."},{"key":"465_CR77","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s12035-013-8489-4","volume":"49","author":"KA Fujita","year":"2014","unstructured":"Fujita, K. A. et al. Integrating pathways of Parkinson\u2019s disease in a molecular interaction map. Mol. Neurobiol. 49, 88\u2013102 (2014).","journal-title":"Mol. Neurobiol."},{"key":"465_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/1752-0509-6-52","volume":"6","author":"S Mizuno","year":"2012","unstructured":"Mizuno, S. et al. AlzPathway: a comprehensive map of signaling pathways of Alzheimer\u2019s disease. BMC Syst. Biol. 6, 52 (2012).","journal-title":"BMC Syst. Biol."},{"key":"465_CR79","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/nature08227","volume":"461","author":"M Scheffer","year":"2009","unstructured":"Scheffer, M. et al. Early-warning signals for critical transitions. Nature 461, 53\u201359 (2009).","journal-title":"Nature"},{"key":"465_CR80","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1046\/j.1460-9568.1998.00090.x","volume":"10","author":"CE Elger","year":"1998","unstructured":"Elger, C. E. & Lehnertz, K. Seizure prediction by non-linear time series analysis of brain electrical activity. Eur. J. Neurosci. 10, 786\u2013789 (1998).","journal-title":"Eur. J. Neurosci."},{"key":"465_CR81","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/brain\/awl241","volume":"130","author":"F Mormann","year":"2007","unstructured":"Mormann, F., Andrzejak, R. G., Elger, C. E. & Lehnertz, K. Seizure prediction: the long and winding road. Brain 130, 314\u2013333 (2007).","journal-title":"Brain"},{"key":"465_CR82","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1474-4422(13)70075-9","volume":"12","author":"MJ Cook","year":"2013","unstructured":"Cook, M. J. et al. Prediction of seizure likelihood with a long-term, implanted seizure advisory system in patients with drug-resistant epilepsy: a first-in-man study. Lancet Neurol. 12, 563\u2013571 (2013).","journal-title":"Lancet Neurol."},{"key":"465_CR83","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/s41582-018-0055-2","volume":"14","author":"L Kuhlmann","year":"2018","unstructured":"Kuhlmann, L., Lehnertz, K., Richardson, M. P., Schelter, B. & Zaveri, H. P. Seizure prediction \u2013 ready for a new era. Nat. Rev. Neurol. 14, 618\u2013630 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"465_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/srep00342","volume":"2","author":"L Chen","year":"2012","unstructured":"Chen, L., Liu, R., Liu, Z. P., Li, M. & Aihara, K. Detecting early-warning signals for sudden deterioration of complex diseases by dynamical network biomarkers. Sci. Rep. 2, 342 (2012).","journal-title":"Sci. Rep."},{"key":"465_CR85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1005633","volume":"13","author":"X Liu","year":"2017","unstructured":"Liu, X. et al. Quantifying critical states of complex diseases using single-sample dynamic network biomarkers. PLoS Comput. Biol. 13, e1005633 (2017).","journal-title":"PLoS Comput. Biol."},{"key":"465_CR86","doi-asserted-by":"crossref","unstructured":"Kay, C., Hayden, M. R. & Leavitt, B. R. in Huntington Disease Ch. 3 (eds Feigin, S. A. & Anderson, K. E.) 31\u201346 (Elsevier, 2017). [Series Handbook of Clinical Neurology Vol. 144].","DOI":"10.1016\/B978-0-12-801893-4.00003-1"},{"key":"465_CR87","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/mdc3.12388","volume":"4","author":"GB Landwehrmeyer","year":"2017","unstructured":"Landwehrmeyer, G. B. et al. Data analytics from Enroll-HD, a global clinical research platform for Huntington\u2019s disease. Mov. Disord. Clin. Pract. 4, 212\u2013224 (2017).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"465_CR88","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"CA Ross","year":"2011","unstructured":"Ross, C. A. & Tabrizi, S. J. Huntington\u2019s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 10, 83\u201398 (2011).","journal-title":"Lancet Neurol."},{"key":"465_CR89","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/ng0893-387","volume":"4","author":"M Duyao","year":"1993","unstructured":"Duyao, M. et al. Trinucleotide repeat length instability and age of onset in Huntington\u2019s disease. Nat. Genet. 4, 387\u2013392 (1993).","journal-title":"Nat. Genet."},{"key":"465_CR90","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"ME MacDonald","year":"1993","unstructured":"MacDonald, M. E. et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72, 971\u2013983 (1993).","journal-title":"Cell"},{"key":"465_CR91","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1212\/01.wnl.0000204230.16619.d9","volume":"66","author":"A Rosenblatt","year":"2006","unstructured":"Rosenblatt, A. et al. The association of CAG repeat length with clinical progression in Huntington disease. Neurology 66, 1016\u20131020 (2006).","journal-title":"Neurology"},{"key":"465_CR92","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/ajmg.b.20110","volume":"125B","author":"M Cannella","year":"2004","unstructured":"Cannella, M. et al. The gender effect in juvenile Huntington disease patients of Italian origin. Am. J. Med. Genet. 125B, 92\u201398 (2004).","journal-title":"Am. J. Med. Genet."},{"key":"465_CR93","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1093\/hmg\/ddp242","volume":"15","author":"M Swami","year":"2009","unstructured":"Swami, M. et al. Somatic expansion of the Huntington\u2019s disease CAG repeat in the brain is associated with an earlier age of disease onset. Hum. Mol. Genet. 15, 3039\u20133047 (2009).","journal-title":"Hum. Mol. Genet."},{"key":"465_CR94","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1093\/hmg\/ddg352","volume":"12","author":"L Kennedy","year":"2003","unstructured":"Kennedy, L. et al. Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum. Mol. Genet. 12, 3359\u20133367 (2003).","journal-title":"Hum. Mol. Genet."},{"key":"465_CR95","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","volume":"65","author":"DR Langbehn","year":"2004","unstructured":"Langbehn, D. R. et al. A new model for prediction of the age of onset and penetrance for Huntington\u2019s disease based on CAG length. Clin. Genet. 65, 267\u2013277 (2004).","journal-title":"Clin. Genet."},{"key":"465_CR96","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1073\/pnas.0308679101","volume":"101","author":"NS Wexler","year":"2004","unstructured":"Wexler, N. S. et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington\u2019s disease age of onset. Proc. Natl Acad. Sci. USA 101, 3498\u20133503 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"465_CR97","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S1474-4422(20)30343-4","volume":"19","author":"GEB Wright","year":"2020","unstructured":"Wright, G. E. B. et al. Interrupting sequence variants and age of onset in Huntington\u2019s disease: clinical implications and emerging therapies. Lancet Neurol. 19, 930\u2013939 (2020).","journal-title":"Lancet Neurol."},{"key":"465_CR98","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.ajhg.2019.04.007","volume":"104","author":"GEB Wright","year":"2019","unstructured":"Wright, G. E. B. et al. Length of uninterrupted CAG, independent of polyglutamine size, results in increased somatic instability, hastening onset of Huntington disease. Am. J. Hum. Genet. 104, 1116\u20131126 (2019).","journal-title":"Am. J. Hum. Genet."},{"key":"465_CR99","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.cell.2019.06.036","volume":"178","author":"JM Lee","year":"2019","unstructured":"Lee, J. M. et al. CAG repeat not polyglutamine length determines timing of Huntington\u2019s disease onset. Cell 178, 887\u2013900.e14 (2019).","journal-title":"Cell"},{"key":"465_CR100","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1086\/378133","volume":"73","author":"JL Li","year":"2003","unstructured":"Li, J. L. et al. A genome scan for modifiers of age at onset in Huntington disease: the HD MAPS study. Am. J. Hum. Genet. 73, 682\u2013687 (2003).","journal-title":"Am. J. Hum. Genet."},{"key":"465_CR101","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.cell.2015.07.003","volume":"162","author":"JM Lee","year":"2015","unstructured":"Lee, J. M. et al. Identification of genetic factors that modify clinical onset of Huntington\u2019s disease. Cell 162, 516\u2013526 (2015).","journal-title":"Cell"},{"key":"465_CR102","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"[No authors listed]","year":"1996","unstructured":"[No authors listed]. Unified Huntington\u2019s disease rating scale: reliability and consistency. Mov. Disord. 11, 136\u2013142 (1996).","journal-title":"Mov. Disord."},{"key":"465_CR103","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1002\/mds.25663","volume":"28","author":"S Franciosi","year":"2013","unstructured":"Franciosi, S., Shim, Y., Lau, M., Hayden, M. R. & Leavitt, B. R. A systematic review and meta-analysis of clinical variables used in Huntington disease research. Mov. Disord. 28, 1987\u20131994 (2013).","journal-title":"Mov. Disord."},{"key":"465_CR104","doi-asserted-by":"crossref","unstructured":"Reilmann, R. & Schubert, R. in Huntington Disease Ch. 18 (eds Feigin, S. A. & Anderson, K. E.) 209\u2013225 (Elsevier, 2017). [Series Handbook of Clinical Neurology Vol 144].","DOI":"10.1016\/B978-0-12-801893-4.00018-3"},{"key":"465_CR105","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/mdc3.12824","volume":"6","author":"M Caligiuri","year":"2019","unstructured":"Caligiuri, M., Snell, C., Park, S. & Corey-Bloom, J. Handwriting movement abnormalities in symptomatic and premanifest Huntington\u2019s disease. Mov. Disord. Clin. Pract. 6, 586\u2013592 (2019).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"465_CR106","doi-asserted-by":"publisher","first-page":"eaat7108","DOI":"10.1126\/scitranslmed.aat7108","volume":"10","author":"LM Byrne","year":"2018","unstructured":"Byrne, L. M. et al. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington\u2019s disease. Sci. Transl. Med. 10, eaat7108 (2018).","journal-title":"Sci. Transl. Med."},{"key":"465_CR107","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.mcn.2019.02.004","volume":"97","author":"P Zeun","year":"2019","unstructured":"Zeun, P., Scahill, R. I., Tabrizi, S. J. & Wild, E. J. Fluid and imaging biomarkers for Huntington\u2019s disease. Mol. Cell. Neurosci. 97, 67\u201380 (2019).","journal-title":"Mol. Cell. Neurosci."},{"key":"465_CR108","doi-asserted-by":"publisher","first-page":"102099","DOI":"10.1016\/j.nicl.2019.102099","volume":"25","author":"CP Pflanz","year":"2020","unstructured":"Pflanz, C. P. et al. One-year changes in brain microstructure differentiate preclinical Huntington\u2019s disease stages. NeuroImage Clin. 25, 102099 (2020).","journal-title":"NeuroImage Clin."},{"key":"465_CR109","doi-asserted-by":"crossref","unstructured":"Nance, M. A. in Huntington Disease Ch. 1 (eds Feigin, S. A. & Anderson, K. E.) 3\u201314 (Elsevier, 2017). [Series Handbook of Clinical Neurology Vol. 144].","DOI":"10.1016\/B978-0-12-801893-4.00001-8"},{"key":"465_CR110","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/ana.25709","volume":"87","author":"PA Wijeratne","year":"2020","unstructured":"Wijeratne, P. A. et al. Robust markers and sample sizes for multicenter trials of Huntington disease. Ann. Neurol. 87, 751\u2013762 (2020).","journal-title":"Ann. Neurol."},{"key":"465_CR111","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1002\/stem.1135","volume":"30","author":"I Jeon","year":"2012","unstructured":"Jeon, I. et al. Neuronal properties, in vivo effects, and pathology of a Huntington\u2019s disease patient-derived induced pluripotent stem cells. Stem Cell 30, 2054\u20132062 (2012).","journal-title":"Stem Cell"},{"key":"465_CR112","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.stem.2012.04.026","volume":"11","author":"MC An","year":"2012","unstructured":"An, M. C. et al. Genetic correction of Huntington\u2019s disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 11, 253\u2013263 (2012).","journal-title":"Cell Stem Cell"},{"key":"465_CR113","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1042\/BJ20111495","volume":"446","author":"JIL Chae","year":"2012","unstructured":"Chae, J. I. L. et al. Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington\u2019s disease patient. Biochem. J. 446, 359\u2013371 (2012).","journal-title":"Biochem. J."},{"key":"465_CR114","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3389\/fnins.2018.00800","volume":"12","author":"J Sassone","year":"2018","unstructured":"Sassone, J., Papadimitriou, E. & Thomaidou, D. Regenerative approaches in Huntington\u2019s disease: from mechanistic insights to therapeutic protocols. Front. Neurosci. 12, 800 (2018).","journal-title":"Front. Neurosci."},{"key":"465_CR115","doi-asserted-by":"publisher","first-page":"E762","DOI":"10.1073\/pnas.1715865115","volume":"115","author":"P Conforti","year":"2018","unstructured":"Conforti, P. et al. Faulty neuronal determination and cell polarization are reverted by modulating HD early phenotypes. Proc. Natl Acad. Sci. USA 115, E762\u2013E771 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"465_CR116","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1007\/s12035-017-0477-7","volume":"55","author":"K Wiatr","year":"2018","unstructured":"Wiatr, K., Szlachcic, W. J., Trzeciak, M., Figlerowicz, M. & Figiel, M. Huntington disease as a neurodevelopmental disorder and early signs of the disease in stem cells. Mol. Neurobiol. 55, 3351\u20133371 (2018).","journal-title":"Mol. Neurobiol."},{"key":"465_CR117","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/nn.4598","volume":"20","author":"RG Lim","year":"2017","unstructured":"Lim, R. G. et al. Developmental alterations in Huntington\u2019s disease neural cells and pharmacological rescue in cells and mice. Nat. Neurosci. 20, 648\u2013660 (2017).","journal-title":"Nat. Neurosci."},{"key":"465_CR118","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/s41587-019-0237-5","volume":"37","author":"T Haremaki","year":"2019","unstructured":"Haremaki, T. et al. Self-organizing neuruloids model developmental aspects of Huntington\u2019s disease in the ectodermal compartment. Nat. Biotechnol. 37, 1198\u20131208 (2019).","journal-title":"Nat. Biotechnol."},{"key":"465_CR119","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/S1474-4422(17)30161-8","volume":"16","author":"DJH Moss","year":"2017","unstructured":"Moss, D. J. H. et al. Identification of genetic variants associated with Huntington\u2019s disease progression: a genome-wide association study. Lancet Neurol. 16, 701\u2013711 (2017).","journal-title":"Lancet Neurol."},{"key":"465_CR120","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ddmod.2019.01.001","volume":"27","author":"L B\u00f6hnke","year":"2018","unstructured":"B\u00f6hnke, L., Traxler, L., Herdy, J. R. & Mertens, J. Human neurons to model aging: a dish best served old. Drug Discov. Today Dis. Models 27, 43\u201349 (2018).","journal-title":"Drug Discov. Today Dis. Models"},{"key":"465_CR121","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41418-020-0566-4","volume":"28","author":"J Sidhaye","year":"2021","unstructured":"Sidhaye, J. & Knoblich, J. A. Brain organoids: an ensemble of bioassays to investigate human neurodevelopment and disease. Cell Death Differ. 28, 52\u201367 (2021).","journal-title":"Cell Death Differ."},{"key":"465_CR122","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1038\/s41587-020-0525-0","volume":"38","author":"P Rifes","year":"2020","unstructured":"Rifes, P. et al. Modeling neural tube development by differentiation of human embryonic stem cells in a microfluidic WNT gradient. Nat. Biotechnol. 38, 1265\u20131273 (2020).","journal-title":"Nat. Biotechnol."},{"key":"465_CR123","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/cpt.896","volume":"103","author":"J Vicente","year":"2018","unstructured":"Vicente, J. et al. Mechanistic model-informed proarrhythmic risk assessment of drugs: review of the \u201cCiPA\u201d initiative and design of a prospective clinical validation study. Clin. Pharmacol. Ther. 103, 54\u201366 (2018).","journal-title":"Clin. Pharmacol. Ther."},{"key":"465_CR124","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/cts.12674","volume":"12","author":"K Blinova","year":"2019","unstructured":"Blinova, K. et al. Clinical trial in a dish: personalized stem cell derived cardiomyocyte assay compared to clinical trial results for two QT prolonging drugs. Clin. Transl. Sci. 12, 687\u2013697 (2019).","journal-title":"Clin. Transl. Sci."},{"key":"465_CR125","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1073\/pnas.0811729106","volume":"106","author":"R Biggs","year":"2009","unstructured":"Biggs, R., Carpenter, S. R. & Brock, W. A. Turning back from the brink: detecting an impending regime shift in time to avert it. Proc. Natl Acad. Sci. USA 106, 826\u2013831 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"465_CR126","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nbt1374","volume":"26","author":"M Nakagawa","year":"2008","unstructured":"Nakagawa, M. et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat. Biotechnol. 26, 101\u2013106 (2008).","journal-title":"Nat. Biotechnol."},{"key":"465_CR127","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nature05934","volume":"448","author":"K Okita","year":"2007","unstructured":"Okita, K., Ichisaka, T. & Yamanaka, S. Generation of germline-competent induced pluripotent stem cells. Nature 448, 313\u2013317 (2007).","journal-title":"Nature"},{"key":"465_CR128","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc1780","volume":"6","author":"BD Rowland","year":"2006","unstructured":"Rowland, B. D. & Peeper, D. S. KLF4, p21 and context-dependent opposing forces in cancer. Nat. Rev. Cancer 6, 11\u201323 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"465_CR129","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nature22312","volume":"545","author":"FT Merkle","year":"2017","unstructured":"Merkle, F. T. et al. Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature 545, 229\u2013233 (2017).","journal-title":"Nature"},{"key":"465_CR130","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nrm1703","volume":"6","author":"S Adhikary","year":"2005","unstructured":"Adhikary, S. & Eilers, M. Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol. 6, 635\u2013645 (2005).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"465_CR131","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.gene.2013.01.009","volume":"519","author":"W Zheng","year":"2013","unstructured":"Zheng, W., Wang, Y., Chang, T., Huang, H. & Yee, J. K. Significant differences in genotoxicity induced by retrovirus integration in human T cells and induced pluripotent stem cells. Gene 519, 142\u2013149 (2013).","journal-title":"Gene"},{"key":"465_CR132","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.celrep.2018.06.091","volume":"24","author":"M D\u2019Antonio","year":"2018","unstructured":"D\u2019Antonio, M. et al. Insights into the mutational burden of human induced pluripotent stem cells from an integrative multi-omics approach. Cell Rep. 24, 883\u2013894 (2018).","journal-title":"Cell Rep."},{"key":"465_CR133","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/nature13551","volume":"511","author":"H Ma","year":"2014","unstructured":"Ma, H. et al. Abnormalities in human pluripotent cells due to reprogramming mechanisms. Nature 511, 177\u2013183 (2014).","journal-title":"Nature"},{"key":"465_CR134","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fcvm.2018.00004","volume":"5","author":"ET Str\u00e4ssler","year":"2018","unstructured":"Str\u00e4ssler, E. T., Aalto-Set\u00e4l\u00e4, K., Kiamehr, M., Landmesser, U. & Kr\u00e4nkel, N. Age is relative\u2013impact of donor age on induced pluripotent stem cell-derived cell functionality. Front. Cardiovasc. Med. 5, 4 (2018).","journal-title":"Front. Cardiovasc. Med."},{"key":"465_CR135","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature09798","volume":"471","author":"R Lister","year":"2011","unstructured":"Lister, R. et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 471, 68\u201373 (2011).","journal-title":"Nature"},{"key":"465_CR136","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2156-14-32","volume":"14","author":"H Hiura","year":"2013","unstructured":"Hiura, H. et al. Stability of genomic imprinting in human induced pluripotent stem cells. BMC Genet. 14, 32 (2013).","journal-title":"BMC Genet."},{"key":"465_CR137","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1002\/stem.205","volume":"27","author":"M Pick","year":"2009","unstructured":"Pick, M. et al. Clone- and gene-specific aberrations of parental imprinting in human induced pluripotent stem cell. Stem Cells 27, 2686\u20132690 (2009).","journal-title":"Stem Cells"},{"key":"465_CR138","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3389\/fcell.2019.00076","volume":"7","author":"V Perrera","year":"2019","unstructured":"Perrera, V. & Martello, G. How does reprogramming to pluripotency affect genomic imprinting? Front. Cell Dev. Biol. 7, 76 (2019).","journal-title":"Front. Cell Dev. Biol."},{"key":"465_CR139","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.stem.2012.03.008","volume":"11","author":"MC Anguera","year":"2012","unstructured":"Anguera, M. C. et al. Molecular signatures of human induced pluripotent stem cells highlight sex differences and cancer genes. Cell Stem Cell 11, 75\u201390 (2012).","journal-title":"Cell Stem Cell"},{"key":"465_CR140","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.stem.2015.03.016","volume":"16","author":"C Vallot","year":"2015","unstructured":"Vallot, C. et al. Erosion of X chromosome inactivation in human pluripotent cells initiates with XACT coating and depends on a specific heterochromatin landscape. Cell Stem Cell 16, 533\u2013546 (2015).","journal-title":"Cell Stem Cell"},{"key":"465_CR141","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.15252\/embj.201591267","volume":"34","author":"JK Ichida","year":"2015","unstructured":"Ichida, J. K. & Kiskinis, E. Probing disorders of the nervous system using reprogramming approaches. EMBO J. 34, 1456\u20131477 (2015).","journal-title":"EMBO J."},{"key":"465_CR142","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13024-016-0092-5","volume":"11","author":"ED Nekrasov","year":"2016","unstructured":"Nekrasov, E. D. et al. Manifestation of Huntington\u2019s disease pathology in human induced pluripotent stem cell-derived neurons. Mol. Neurodegener. 11, 27 (2016).","journal-title":"Mol. Neurodegener."},{"key":"465_CR143","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2217\/rme-2018-0095","volume":"13","author":"S Sullivan","year":"2018","unstructured":"Sullivan, S. et al. Quality control guidelines for clinical-grade human induced pluripotent stem cell lines. Regen. Med. 13, 859\u2013866 (2018).","journal-title":"Regen. Med."},{"key":"465_CR144","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1073\/pnas.41.5.321","volume":"41","author":"TJ King","year":"1955","unstructured":"King, T. J. & Briggs, R. Changes in the nuclei of differentiating gastrula cells, as demonstrated by nuclear transplantation. Proc. Natl Acad. Sci. USA 41, 321\u2013325 (1955).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"465_CR145","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/182064a0","volume":"182","author":"JB Gurdon","year":"1958","unstructured":"Gurdon, J. B., Elsdale, T. R. & Fischberg, M. Sexually mature individuals of Xenopus laevis from the transplantation of single somatic nuclei. Nature 182, 64\u201365 (1958).","journal-title":"Nature"},{"key":"465_CR146","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1126\/science.6857250","volume":"220","author":"J McGrath","year":"1983","unstructured":"McGrath, J. & Solter, D. Nuclear transplantation in the mouse embryo by microsurgery and cell fusion. Science 220, 1300\u20131302 (1983).","journal-title":"Science"},{"key":"465_CR147","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/380064a0","volume":"380","author":"KHS Campbell","year":"1996","unstructured":"Campbell, K. H. S., McWhir, J., Ritchie, W. A. & Wilmut, I. Sheep cloned by nuclear transfer from a cultured cell line. Nature 380, 64\u201366 (1996).","journal-title":"Nature"},{"key":"465_CR148","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663\u2013676 (2006).","journal-title":"Cell"},{"key":"465_CR149","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/0092-8674(87)90585-X","volume":"51","author":"RL Davis","year":"1987","unstructured":"Davis, R. L., Weintraub, H. & Lassar, A. B. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 51, 987\u20131000 (1987).","journal-title":"Cell"},{"key":"465_CR150","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/nature08797","volume":"463","author":"T Vierbuchen","year":"2010","unstructured":"Vierbuchen, T. et al. Direct conversion of fibroblasts to functional neurons by defined factors. Nature 463, 1035\u20131041 (2010).","journal-title":"Nature"},{"key":"465_CR151","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJMoa1608368","volume":"376","author":"M Mandai","year":"2017","unstructured":"Mandai, M. et al. Autologous induced stem-cell-derived retinal cells for macular degeneration. N. Engl. J. Med. 376, 1038\u20131046 (2017).","journal-title":"N. Engl. J. Med."},{"key":"465_CR152","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/d41586-020-01285-w","volume":"581","author":"S Mallapaty","year":"2020","unstructured":"Mallapaty, S. Revealed: two men in China were first to receive pioneering stem-cell treatment for heart disease. Nature 581, 249\u2013250 (2020).","journal-title":"Nature"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-021-00465-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-021-00465-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-021-00465-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T17:27:17Z","timestamp":1733938037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-021-00465-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,3]]},"references-count":152,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["465"],"URL":"https:\/\/doi.org\/10.1038\/s41582-021-00465-0","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739676940.793593610","asserted-by":"object"}]},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,3]]},"assertion":[{"value":"27 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}